acp-501
mAbexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2012 (NCT01554800)
Timeline
Indications
Mechanism of action
- Phosphatidylcholine-sterol acyltransferaseImmunity, passive
LCAT immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- acp-501
- medi6012
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03773172 | Phase 2 | Jan 31, 2019 | AstraZeneca, Columbia University, MedImmune |
| NCT03578809 | Phase 2 | Jun 5, 2018 | Thrombolysis in Myocardial Infarction Study Group |
| NCT03004638 | Phase 2 | Jan 23, 2017 | MedImmune |
| NCT02601560 | Phase 2 | Dec 1, 2015 | MedImmune |
| NCT01554800 | Phase 1 | Mar 1, 2012 | AlphaCore Pharma LLC, National Heart, Lung, and Blood Institute (NHLBI) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 3 | 2 | 1 | 2015 |
| AlphaCore Pharma LLC | For profit | 1 | 1 | 1 | 2012 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2019 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2012 |
| Thrombolysis in Myocardial Infarction Study Group | Academic/Hospital | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1